ArticleCell2021
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 88 citations in OpenAlex.
- Article
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanistic and antigenic boundaries of Henipavirus and Parahenipavirus glycoproteins.Nature communications · 2026Article
- Structural Insights Into ManAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.Journal of virology · 2025Article
- Article
- The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.Nature reviews. Microbiology · 2025Review
- Potent Cross-neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Comparison of enriched charge variants from different anti-CD3 bispecific antibodies reveals differential susceptibility of each bispecific arm to post-translational modification.Protein science : a publication of the Protein Society · 2025Article
- 50 Years of Antibody Numbering Schemes: A Statistical and Structural Evaluation Reveals Key Differences and Limitations.Antibodies (Basel, Switzerland) · 2024Article
- HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state.Computational and structural biotechnology journal · 2024Article
- Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.Nature communications · 2024Article
- Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation.Nature communications · 2024Article
- Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families.PLoS pathogens · 2024Article
- Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen Vaccine Delivery.Bioconjugate chemistry · 2024Article
- SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition.Molecular cell · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 9 institutions in 2 countries.
Wilton B WilliamsDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.
R Ryan MeyerhoffDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
R J EdwardsDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Hui LiPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kartik ManneDuke Human Vaccine Institute, Durham, NC 27710, USA.
Nathan I NicelyDuke Human Vaccine Institute, Durham, NC 27710, USA.
Rory HendersonDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Ye ZhouDepartment of Computer Science, Duke University, Durham, NC 27708, USA.
Katarzyna JanowskaDuke Human Vaccine Institute, Durham, NC 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Durham, NC 27710, USA.
Sophie GobeilDuke Human Vaccine Institute, Durham, NC 27710, USA.
Tyler EvangelousDuke Human Vaccine Institute, Durham, NC 27710, USA.
Bhavna HoraDuke Human Vaccine Institute, Durham, NC 27710, USA.
Madison BerryDuke Human Vaccine Institute, Durham, NC 27710, USA.
A Yousef AbuahmadDuke Human Vaccine Institute, Durham, NC 27710, USA.
Jordan SprenzDuke Human Vaccine Institute, Durham, NC 27710, USA.
Margaret DeytonDuke Human Vaccine Institute, Durham, NC 27710, USA.
Victoria StallsDuke Human Vaccine Institute, Durham, NC 27710, USA.
Megan KoppDuke Human Vaccine Institute, Durham, NC 27710, USA.
Allen L HsuGenome Integrity and Structural Biology Laboratory, NIEHS, NIH, Department of Health and Human Services, Research Triangle Park, NC 27709, USA.
Mario J BorgniaGenome Integrity and Structural Biology Laboratory, NIEHS, NIH, Department of Health and Human Services, Research Triangle Park, NC 27709, USA.
Guillaume B E Stewart-JonesVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Matthew S LeeBoston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Naomi BronkemaDepartment of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA 19081, USA.
M Anthony MoodyDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA; Department of Pediatrics, Duke University, Durham, NC 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Todd BradleyDuke Human Vaccine Institute, Durham, NC 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Robert J ParksDuke Human Vaccine Institute, Durham, NC 27710, USA.
Andrew FoulgerDuke Human Vaccine Institute, Durham, NC 27710, USA.
Thomas OguinDuke Human Vaccine Institute, Durham, NC 27710, USA.
Gregory D SempowskiDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA.
Celia C LaBrancheDepartment of Surgery, Duke University, Durham, NC 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA.
Michael SeamanBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Sampa SantraBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
John PerfectDepartment of Medicine, Duke University, Durham, NC 27710, USA.
Joseph R FrancicaVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Geoffrey M LynnVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA; Avidea Technologies, Inc., Baltimore, MD, USA.
Baptiste AussedatMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
William E WalkowiczMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Richard LagaInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic.
Garnett KelsoeDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA.
Daniela FeraDepartment of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA 19081, USA.
Peter D KwongVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Robert A SederVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Alberto BartesaghiDepartment of Computer Science, Duke University, Durham, NC 27708, USA; Department of Biochemistry, Duke University, Durham, NC 27705, USA; Department of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA.
George M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA. Electronic address: priyamvada.acharya@duke.edu.
Barton F HaynesDuke Human Vaccine Institute, Durham, NC 27710, USA; Department of Medicine, Duke University, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA. Electronic address: hayne002@mc.duke.edu.
Duke University · USNational Institutes of Health · USBeth Israel Deaconess Medical Center · USMemorial Sloan Kettering Cancer Center · USNational Institute of Environmental Health Sciences · USSwarthmore College · USUniversity of Pennsylvania · USBoston Children's Hospital · USCzech Academy of Sciences, Institute of Macromolecular Chemistry · CZ
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI KELSOE, GARNETT H · 2012 to 2018
$204.7MNCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MNeutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6MNIEHS Cryo-EM Core FacilityZICES103326 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BORGNIA, MARIO · 2017 to 2025
$17.0MRegional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MTargeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics developmentR01AI145687 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2019 to 2026
$6.9MNCI NIH HHS P30 CA008748NIAID NIH HHS HHSN272201800004CNIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI120801NIAID NIH HHS R01 AI128832NIAID NIH HHS R01 AI131331NIAID NIH HHS R01 AI140897NIAID NIH HHS R01 AI145687NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI165080NIAID NIH HHS UC6 AI058607NIAID NIH HHS UM1 AI100645NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM136577NIGMS NIH HHS U24 GM129539
Abstract
Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated HIV-1 envelope (Env) as a model antigen. 2G12 is a broadly neutralizing Ab (bnAb) that targets a conserved glycan patch on Env of geographically diverse HIV-1 strains using a unique heavy-chain (V
Indexed as
AnimalsAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing AntibodiesCOVID-19Dimerizationenv Gene Products, Human Immunodeficiency VirusEpitopesGlycosylationHIV-1HIV AntibodiesHIV InfectionsHumansImmunoglobulin Fab FragmentsMacaca mulattaPolysaccharidesAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesImmunoglobulin Fab FragmentsPolysaccharidesReceptors, Antigen, B-CellSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2VaccinesFab dimerizationFDG Absglycan-dependent Ab bindingHIV-1 Env glycansIgM-memory B cellsmarginal zone B cellsnatural AbsSARS-CoV-2 spike glycans
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.